Q-omics provides the consensus-scored LYSMD3 profile across patient tissues and cancer cell-line models. LYSMD3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LYSMD3 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, LYSMD3 RNA expression shows 20,325 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where LYSMD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LYSMD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LYSMD3 survival associations across molecular data types. LYSMD3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LYSMD3 RNA expression–survival associations across cancer types. High LYSMD3 expression shows unfavorable associations in CESC, LGG, UVM and OV, but favorable associations in KIRC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LYSMD3 RNA expression.
This table summarizes LYSMD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LYSMD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LYSMD3 shows lower tumor expression in THCA, LUSC, COAD, LUAD and UCEC and higher tumor expression in KIRC. The THCA box plot shows higher LYSMD3 RNA expression in normal versus tumor tissue (log2 FC = −1.021, t-test p < 0.001).
This table shows molecular features associated with LYSMD3 in patient tissues and cancer cell lines. In patient samples, LYSMD3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LYSMD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
